Newly diagnosed high-risk multiple myeloma: Outcomes and management

High-risk abnormalities, found in 20%–25% of patients with multiple myeloma, lead to inferior survival. This review explores evolving therapies, emphasizing induction strategies and autologous stem cell transplantation. Quadruplet regimens are becoming cornerstone frontline therapy for high-risk MM, showing improved outcomes. Emerging bispecific antibodies and CAR-T cells are actively being integrated and evaluated to further transform the standard of care.